CLINUVEL Non-Executive Director Jack Wood discusses commercialization.
CLINUVEL is developing a breakthrough photoprotective drug, Scenesse (afamelanotide), to be administered every 60 days.
Scenesse is selective in its pharmacologic action by activating skin's own pigment, melanin. It is due to melanin that a physical barrier between skin and light of all wavelengths -particularly UV- is provided.
Medically this is known as photoprotection.
The CLINUVEL team worldwide is testing Scenesse in 5 indications currently in Phase II and III clinical trials.
Eligible for these trials are patients who suffer from UV and light related skin disorders, ranging from those who suffer from porphyrias to those affected by skin cancer.